Merit Medical Systems (Nasdaq:MMSI) announced that it launched the Ventrax delivery system for cardiac interventions.

SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax ...

4). The right aspect of the aneurysm projected between the superior vena cava and ascending aorta but did not distort these structures. The ventricular infundibulum and pulmonary artery on the ...

Aortic valve stenosis” is an often-overlooked condition and a growing health concern in ageing societies such as Thailand.

Systems announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest ...

As the stenosis progresses, a resting gradient develops across the aortic valve. The left ventricle responds by developing hypertrophy to overcome the stenosis. The increased wall thickness helps ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Objective In this study, the impact of regular training on left ventricle morphology in a group of athletes with bicuspid aortic valve (BAV) was evaluated. Design Longitudinal cohort study. A group of ...